CVS Health (CVS) Q1 earnings will beat estimates largely due to favorable medical loss ratio dynamics tied to the Inflation Reduction Act and Medicare Part D and a strong flu season, UBS Securities said in an earnings preview emailed on Tuesday.
The company's stock may not respond significantly unless there is greater clarity on Medical Advantage cost trends and membership mix, according to the preview.
The firm said that retail pharmacy might be protected due to dynamic maximum allowable cost pricing.
UBS said that the company faces regulatory risk if new legislation in Alaska that bans pharmacy benefit managers from owning pharmacies is adopted by other states.
The firm has a neutral rating on CVS stock with a $67 price target.
Price: 65.31, Change: +0.38, Percent Change: +0.59
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.